Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.06
AMGN's Cash to Debt is ranked lower than
79% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. AMGN: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
AMGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 1.03 Max: 8.25
Current: 1.06
0.32
8.25
Equity to Asset 0.40
AMGN's Equity to Asset is ranked lower than
77% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMGN: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
AMGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.56 Max: 0.84
Current: 0.4
0.33
0.84
Interest Coverage 12.42
AMGN's Interest Coverage is ranked lower than
84% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMGN: 12.42 )
Ranked among companies with meaningful Interest Coverage only.
AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 5.3  Med: 8.46 Max: 29.77
Current: 12.42
5.3
29.77
F-Score: 8
Z-Score: 2.89
M-Score: -2.52
WACC vs ROIC
9.68%
27.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 40.73
AMGN's Operating margin (%) is ranked higher than
94% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. AMGN: 40.73 )
Ranked among companies with meaningful Operating margin (%) only.
AMGN' s Operating margin (%) Range Over the Past 10 Years
Min: 26.91  Med: 31.86 Max: 40.73
Current: 40.73
26.91
40.73
Net-margin (%) 33.07
AMGN's Net-margin (%) is ranked higher than
94% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. AMGN: 33.07 )
Ranked among companies with meaningful Net-margin (%) only.
AMGN' s Net-margin (%) Range Over the Past 10 Years
Min: 20.68  Med: 26.36 Max: 33.07
Current: 33.07
20.68
33.07
ROE (%) 26.11
AMGN's ROE (%) is ranked higher than
95% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. AMGN: 26.11 )
Ranked among companies with meaningful ROE (%) only.
AMGN' s ROE (%) Range Over the Past 10 Years
Min: 14.97  Med: 21.29 Max: 26.11
Current: 26.11
14.97
26.11
ROA (%) 10.18
AMGN's ROA (%) is ranked higher than
90% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. AMGN: 10.18 )
Ranked among companies with meaningful ROA (%) only.
AMGN' s ROA (%) Range Over the Past 10 Years
Min: 7.63  Med: 9.3 Max: 12.11
Current: 10.18
7.63
12.11
ROC (Joel Greenblatt) (%) 150.51
AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. AMGN: 150.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 61.87  Med: 79.34 Max: 150.86
Current: 150.51
61.87
150.86
Revenue Growth (3Y)(%) 8.80
AMGN's Revenue Growth (3Y)(%) is ranked higher than
59% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. AMGN: 8.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.8  Med: 15.1 Max: 29.2
Current: 8.8
5.8
29.2
EBITDA Growth (3Y)(%) 19.90
AMGN's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. AMGN: 19.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AMGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.6  Med: 15.7 Max: 25.2
Current: 19.9
-1.6
25.2
EPS Growth (3Y)(%) 18.00
AMGN's EPS Growth (3Y)(%) is ranked higher than
73% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. AMGN: 18.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.3  Med: 17.2 Max: 22.1
Current: 18
2.3
22.1
» AMGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AMGN Guru Trades in Q3 2015

John Hussman 40,000 sh (New)
John Burbank 20,240 sh (New)
First Pacific Advisors 53,260 sh (New)
Andreas Halvorsen 230,298 sh (New)
George Soros 2,100 sh (New)
Pioneer Investments 60,111 sh (+2628.60%)
Ray Dalio 62,033 sh (+45.71%)
Ruane Cunniff 2,017 sh (+24.74%)
First Eagle Investment 551,600 sh (+22.77%)
Daniel Loeb 9,850,000 sh (+9.44%)
RS Investment Management 4,097 sh (+8.10%)
Mairs and Power 11,166 sh (+2.53%)
John Buckingham 58,850 sh (+0.68%)
David Carlson 470,000 sh (unchged)
Vanguard Health Care Fund 5,580,485 sh (unchged)
Lee Ainslie 1,680 sh (unchged)
Alan Fournier Sold Out
Mario Gabelli 40,550 sh (-0.06%)
Dodge & Cox 48,344 sh (-4.84%)
PRIMECAP Management 29,175,871 sh (-6.94%)
Jeremy Grantham 579,426 sh (-7.88%)
Joel Greenblatt 406,106 sh (-11.55%)
Jim Simons 1,564,345 sh (-11.63%)
Ken Fisher 133,632 sh (-13.84%)
Paul Tudor Jones 6,800 sh (-14.73%)
» More
Q4 2015

AMGN Guru Trades in Q4 2015

Louis Moore Bacon 125,000 sh (New)
Pioneer Investments 193,844 sh (+222.48%)
George Soros 4,400 sh (+109.52%)
First Eagle Investment 957,656 sh (+73.61%)
Paul Tudor Jones 8,029 sh (+18.07%)
David Carlson 490,000 sh (+4.26%)
Ken Fisher 136,400 sh (+2.07%)
PRIMECAP Management 29,177,226 sh (unchged)
Lee Ainslie 1,680 sh (unchged)
Ruane Cunniff 2,017 sh (unchged)
Samuel Isaly 396,000 sh (unchged)
Ray Dalio Sold Out
John Burbank Sold Out
Andreas Halvorsen Sold Out
John Buckingham 58,522 sh (-0.56%)
Mairs and Power 11,091 sh (-0.67%)
Vanguard Health Care Fund 5,398,985 sh (-3.25%)
Mario Gabelli 39,175 sh (-3.39%)
Dodge & Cox 46,644 sh (-3.52%)
Daniel Loeb 9,042,900 sh (-8.19%)
RS Investment Management 3,758 sh (-8.27%)
Joel Greenblatt 276,751 sh (-31.85%)
First Pacific Advisors 35,640 sh (-33.08%)
Jeremy Grantham 355,863 sh (-38.58%)
Jim Simons 146,500 sh (-90.64%)
John Hussman 900 sh (-97.75%)
» More
Q1 2016

AMGN Guru Trades in Q1 2016

Jim Simons 481,200 sh (+228.46%)
Lee Ainslie 3,460 sh (+105.95%)
First Eagle Investment 1,235,154 sh (+28.98%)
Joel Greenblatt 323,405 sh (+16.86%)
David Carlson 500,000 sh (+2.04%)
PRIMECAP Management 29,181,826 sh (+0.02%)
RS Investment Management 3,758 sh (unchged)
John Hussman 900 sh (unchged)
First Pacific Advisors Sold Out
Ruane Cunniff Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Vanguard Health Care Fund 5,241,755 sh (-2.91%)
John Buckingham 56,652 sh (-3.20%)
Mario Gabelli 37,210 sh (-5.02%)
Dodge & Cox 43,557 sh (-6.62%)
Mairs and Power 9,916 sh (-10.59%)
Ken Fisher 112,693 sh (-17.38%)
Pioneer Investments 157,866 sh (-18.56%)
Paul Tudor Jones 5,300 sh (-33.99%)
Jeremy Grantham 154,015 sh (-56.72%)
Daniel Loeb 3,000,000 sh (-66.82%)
Samuel Isaly 303,000 sh (-23.48%)
» More
Q2 2016

AMGN Guru Trades in Q2 2016

Third Avenue Management 135,642 sh (New)
Ray Dalio 38,300 sh (New)
Keeley Asset Management Corp 1,325 sh (New)
Manning & Napier Advisors, Inc 69,758 sh (New)
Jim Simons 1,176,445 sh (+144.48%)
Joel Greenblatt 485,933 sh (+50.26%)
Lee Ainslie 3,940 sh (+13.87%)
Paul Tudor Jones 5,669 sh (+6.96%)
Samuel Isaly 402,800 sh (+32.94%)
RS Investment Management 3,758 sh (unchged)
John Hussman 900 sh (unchged)
Mairs and Power 9,916 sh (unchged)
Daniel Loeb Sold Out
John Buckingham 56,382 sh (-0.48%)
Vanguard Health Care Fund 5,190,355 sh (-0.98%)
PRIMECAP Management 28,634,341 sh (-1.88%)
Mario Gabelli 36,325 sh (-2.38%)
Dodge & Cox 41,257 sh (-5.28%)
David Carlson 460,000 sh (-8.00%)
Ken Fisher 101,573 sh (-9.87%)
Pioneer Investments 125,883 sh (-20.26%)
First Eagle Investment 936,565 sh (-24.17%)
Jeremy Grantham 2,799 sh (-98.18%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:NVO, NAS:GILD, NAS:CELG, NAS:BIIB, NAS:SHPG, OTCPK:RHHBY, NAS:REGN, OTCPK:CSLLY, OTCPK:NVZMY, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:BMRN, OTCPK:UCBJF, NAS:INCY, NAS:MDVN, NAS:GRFS, OTCPK:GMXAY, NAS:JAZZ, NAS:ALKS » details
Traded in other countries:AMGN.Argentina, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.

Amgen Inc was incorporated in the State of Delaware on October 31, 1986. It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics. Its Cardiovascular products include Repatha, Corlanor, Inflammation products include Brodalumab, Nephrology, Oncology products include BLINCYTO, Kyprolis, Neulasta, Rilotumumab, Talimogene laherparepvec, Trebananib, Biosimilars, among others. Its geographic areas of operations include USA, Europe and Canada. Certain raw materials, medical devices and components necessary for the commercial and/or clinical manufacturing of the Company's products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be its only sources for such materials. The Company's sales and marketing forces are mainly located in the United States and Europe. Together with its partners, the Company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In the United States, the Company sells to pharmaceutical wholesale distributors. The Company's competitors include Teva Pharmaceutical Industries Ltd., Janssen Biotech, Inc., AbbVie Inc., Merck & Company, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly/Bristol-Myers Squibb Company, Merck KGaA, Genentech, Inc., GlaxoSmithKline PLC, Millennium Pharmaceuticals, Inc., and Celgene Corporation. Some of the Company's patents include Neulasta, NEUPOGEN, Enbrel, XGEVA, Prolia, EPOGEN, Aranesp, Sensipar, Mimpara, Kyprolis, Nplate, Vectibix, and BLINCYTO. The Company's business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 17.47
AMGN's P/E(ttm) is ranked higher than
74% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.85 vs. AMGN: 17.47 )
Ranked among companies with meaningful P/E(ttm) only.
AMGN' s P/E(ttm) Range Over the Past 10 Years
Min: 10.4  Med: 16.74 Max: 30.95
Current: 17.47
10.4
30.95
Forward P/E 15.02
AMGN's Forward P/E is ranked higher than
70% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. AMGN: 15.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.47
AMGN's PE(NRI) is ranked higher than
75% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 17.47 )
Ranked among companies with meaningful PE(NRI) only.
AMGN' s PE(NRI) Range Over the Past 10 Years
Min: 10.4  Med: 16.74 Max: 30.95
Current: 17.47
10.4
30.95
Price/Owner Earnings (ttm) 15.47
AMGN's Price/Owner Earnings (ttm) is ranked higher than
74% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 30.57 vs. AMGN: 15.47 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AMGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.72  Med: 14.02 Max: 29.05
Current: 15.47
9.72
29.05
P/B 4.27
AMGN's P/B is ranked lower than
57% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. AMGN: 4.27 )
Ranked among companies with meaningful P/B only.
AMGN' s P/B Range Over the Past 10 Years
Min: 1.8  Med: 3.56 Max: 5.21
Current: 4.27
1.8
5.21
P/S 5.80
AMGN's P/S is ranked higher than
68% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. AMGN: 5.80 )
Ranked among companies with meaningful P/S only.
AMGN' s P/S Range Over the Past 10 Years
Min: 3.03  Med: 4.36 Max: 8.97
Current: 5.8
3.03
8.97
PFCF 16.02
AMGN's PFCF is ranked higher than
69% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 26.42 vs. AMGN: 16.02 )
Ranked among companies with meaningful PFCF only.
AMGN' s PFCF Range Over the Past 10 Years
Min: 8.85  Med: 13.7 Max: 27.03
Current: 16.02
8.85
27.03
POCF 14.57
AMGN's POCF is ranked higher than
67% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. AMGN: 14.57 )
Ranked among companies with meaningful POCF only.
AMGN' s POCF Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 22.09
Current: 14.57
7.3
22.09
EV-to-EBIT 12.72
AMGN's EV-to-EBIT is ranked higher than
70% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 23.94 vs. AMGN: 12.72 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 13.3 Max: 22.6
Current: 12.72
7.4
22.6
EV-to-EBITDA 10.50
AMGN's EV-to-EBITDA is ranked higher than
73% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 19.79 vs. AMGN: 10.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 10.75 Max: 18.8
Current: 10.5
6.2
18.8
PEG 1.00
AMGN's PEG is ranked higher than
74% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.29 vs. AMGN: 1.00 )
Ranked among companies with meaningful PEG only.
AMGN' s PEG Range Over the Past 10 Years
Min: 0.18  Med: 1.06 Max: 3.05
Current: 1
0.18
3.05
Shiller P/E 29.64
AMGN's Shiller P/E is ranked higher than
67% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 48.47 vs. AMGN: 29.64 )
Ranked among companies with meaningful Shiller P/E only.
AMGN' s Shiller P/E Range Over the Past 10 Years
Min: 17.36  Med: 27.1 Max: 58.54
Current: 29.64
17.36
58.54
Current Ratio 3.97
AMGN's Current Ratio is ranked lower than
53% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. AMGN: 3.97 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.39 Max: 6.33
Current: 3.97
1.31
6.33
Quick Ratio 3.72
AMGN's Quick Ratio is ranked lower than
53% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AMGN: 3.72 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 3.01 Max: 5.75
Current: 3.72
1.17
5.75
Days Inventory 223.50
AMGN's Days Inventory is ranked lower than
73% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 132.42 vs. AMGN: 223.50 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 223.5
219.41
374.86
Days Sales Outstanding 49.99
AMGN's Days Sales Outstanding is ranked higher than
61% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. AMGN: 49.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.64 Max: 67.84
Current: 49.99
46.32
67.84
Days Payable 76.10
AMGN's Days Payable is ranked higher than
61% of the 422 Companies
in the Global Biotechnology industry.

( Industry Median: 53.36 vs. AMGN: 76.10 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 86.19 Max: 117.72
Current: 76.1
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.23
AMGN's Dividend Yield is ranked higher than
94% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. AMGN: 2.23 )
Ranked among companies with meaningful Dividend Yield only.
AMGN' s Dividend Yield Range Over the Past 10 Years
Min: 0.48  Med: 1.63 Max: 2.44
Current: 2.23
0.48
2.44
Dividend Payout 0.37
AMGN's Dividend Payout is ranked lower than
57% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. AMGN: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
AMGN' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.34 Max: 0.56
Current: 0.37
0.22
0.56
Dividend Growth (3y) 29.90
AMGN's Dividend Growth (3y) is ranked higher than
87% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. AMGN: 29.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AMGN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 63.3
Current: 29.9
0
63.3
Forward Dividend Yield 2.33
AMGN's Forward Dividend Yield is ranked higher than
96% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.20 vs. AMGN: 2.33 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.23
AMGN's Yield on cost (5-Year) is ranked higher than
88% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. AMGN: 2.23 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AMGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.48  Med: 1.63 Max: 2.44
Current: 2.23
0.48
2.44
3-Year Average Share Buyback Ratio 0.10
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. AMGN: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.2  Med: 1.7 Max: 8.7
Current: 0.1
-8.2
8.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 29.96
AMGN's Price/Tangible Book is ranked lower than
93% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. AMGN: 29.96 )
Ranked among companies with meaningful Price/Tangible Book only.
AMGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.67  Med: 13.94 Max: 150.81
Current: 29.96
4.67
150.81
Price/Projected FCF 1.08
AMGN's Price/Projected FCF is ranked higher than
85% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. AMGN: 1.08 )
Ranked among companies with meaningful Price/Projected FCF only.
AMGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.15 Max: 6.23
Current: 1.08
0.59
6.23
Price/DCF (Earnings Based) 1.01
AMGN's Price/DCF (Earnings Based) is ranked higher than
53% of the 19 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. AMGN: 1.01 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.33
AMGN's Price/Median PS Value is ranked lower than
69% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AMGN: 1.33 )
Ranked among companies with meaningful Price/Median PS Value only.
AMGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.72  Med: 1.39 Max: 5.15
Current: 1.33
0.72
5.15
Price/Peter Lynch Fair Value 0.81
AMGN's Price/Peter Lynch Fair Value is ranked higher than
79% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 1.52 vs. AMGN: 0.81 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMGN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.4 Max: 3.34
Current: 0.81
0.58
3.34
Price/Graham Number 4.83
AMGN's Price/Graham Number is ranked lower than
70% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.78 vs. AMGN: 4.83 )
Ranked among companies with meaningful Price/Graham Number only.
AMGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.52  Med: 4.13 Max: 11.67
Current: 4.83
1.52
11.67
Earnings Yield (Greenblatt) (%) 7.84
AMGN's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. AMGN: 7.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.4  Med: 7.5 Max: 13.6
Current: 7.84
4.4
13.6
Forward Rate of Return (Yacktman) (%) 26.57
AMGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 117 Companies
in the Global Biotechnology industry.

( Industry Median: 16.42 vs. AMGN: 26.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2  Med: 17.6 Max: 95.7
Current: 26.57
2
95.7

More Statistics

Revenue (TTM) (Mil) $22,474
EPS (TTM) $ 9.77
Beta1.29
Short Percentage of Float1.23%
52-Week Range $130.09 - 176.64
Shares Outstanding (Mil)748.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22,762 23,502 23,883
EPS ($) 11.40 12.21 13.05
EPS w/o NRI ($) 11.40 12.21 13.05
EPS Growth Rate
(3Y to 5Y Estimate)
2.90%
Dividends Per Share ($) 3.97 4.77
» More Articles for NAS:AMGN

Headlines

Articles On GuruFocus.com
21 Best Undervalued Stocks of the Week Aug 30 2016 
Martin Whitman’s Third Avenue Management Purchases 8 Stocks Aug 12 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 12 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 04 2016 
Can Novartis Win the Entresto Bet? Aug 03 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter Jul 27 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
John Buckingham Touts Apple, Gilead, Amgen May 11 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 

More From Other Websites
These Stocks are Predicted to Outperform this Week According to Forcerank Aug 30 2016
Amgen (AMGN) Reports Positive Data on Prolia and Repatha Aug 30 2016
2:52 am Amgen presents new data for Repatha indicating efficacy and safety across risk groups Aug 30 2016
Regeneron/Sanofi Present Positive Phase III Praluent Data Aug 29 2016
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients... Aug 29 2016
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients... Aug 29 2016
3 Trades for an Upward Surprise Move in Amgen Aug 29 2016
New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented... Aug 29 2016
New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented... Aug 29 2016
Time to Shift Your Focus Aug 28 2016
What Tidings From the Tetons? Long-Awaited Yellen Speech Today Aug 26 2016
[$$] Don't Expect an Amgen Breakup Aug 26 2016
Analyzing Goldman Sachs’s Stock Picks with Growing Dividends Aug 26 2016
Coverage initiated on Amgen by Gabelli & Co Aug 26 2016
Mylan offers price plan to help patients but its programs are still short on details Aug 26 2016
ADXS: Multiple Progresses Have Been Made Aug 25 2016
Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection Aug 25 2016
Short Sellers Increase Bets in Major Biotechs Aug 25 2016
Amgen Gets CRL for Secondary Hyperparathyroidism Drug Aug 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)